[ad_1] Genmab A/S Media Release COPENHAGEN, Denmark; November 9, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de Winkel, Ph.D. and Chief Financial Officer,…
Tag: Genmab
Grant of Restricted Stock Units and Warrants to Employees in Genmab
[ad_1] Company Announcement COPENHAGEN, Denmark; September 28, 2023 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 7,609 restricted stock units and 7,873 warrants to employees…
Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference
[ad_1] Media Release COPENHAGEN, Denmark; August 28, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano…
COPENHAGEN, Denmark; July 28, 2023 – Genmab A/S (Nasdaq : GMAB) announced today its preliminary first half 2023 financial results and its updated 2023 financial guidance – Form 6-K
[ad_1] translational research and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, next-generation immune checkpoint modulators, effector function enhanced antibodies and antibody-drug conjugates. To help…
Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023
[ad_1] We recognize you are attempting to access this website from a country belonging to the European Economic Area (EEA) including the EU which enforces the General Data Protection Regulation…
Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
[ad_1] Company Announcement COPENHAGEN, Denmark; April 24, 2023 – Genmab A/S (Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in…
Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
[ad_1] Company Announcement COPENHAGEN, Denmark; April 21, 2023 – Genmab A/S (Nasdaq: GMAB) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, Inc.…
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab
[ad_1] Company Announcement COPENHAGEN, Denmark; March 29, 2023 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 29, 2023, the Company’s Board of Directors met…